logo
  

Omeros Confirms Submission Of Response To FDA On BLA For Narsoplimab In Treatment Of HSCT-TMA

Omeros Corp. (OMER) confirmed Wednesday that earlier this month the company submitted to the U.S. Food and Drug Administration its response to the Agency's complete Response Letter or CRL for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy or HSCT-TMA.

The company noted that the response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory and legal experts that addresses in detail the points raised by FDA in its CRL for narsoplimab.

Omeros concurrently requested a Type A meeting with FDA to resolve any outstanding items.

Narsoplimab is the first drug candidate submitted to FDA for approval in HSCT-TMA. It has Breakthrough Therapy and Orphan designations in both HSCT-TMA and IgA nephropathy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
RELATED NEWS
Follow RTT